Posted 5 October, 2026
Iowa joined a coalition of 43 states and territories seeking court approval of a $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals Inc. to resolve allegations that the generic drug manufacturers engaged in a widespread, long-running conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade with regard to numerous generic prescription drugs. The coalition reached a settlement in principle on August 3rd, 2026, and all 43 states and territories have since signed onto the agreement. A motion for preliminary approval of the settlement will be filed today in the United States District Court for the District of Connecticut in Hartford.
Under the terms of this agreement and previous settlements Sandoz reached with other states, Sandoz will pay a total of approximately $469 million to settle the claims brought by state enforcers. The settlement will also resolve allegations that Sandoz Inc.’s past and present international affiliates, Novartis AG, Sandoz AG, and Sandoz Group AG, participated in the alleged anticompetitive conduct and fraudulently transferred assets to avoid liability. As part of the settlement, Sandoz has agreed to meaningful meaning ful changes including a series of internal reforms to ensure fair competition and compliance with antitrust laws.
Iowa’s share of today’s settlement is $1,380,384.01.
This latest settlement comes as the coalition prepares for the first trial to be held in Hartford, Connecticut in February 2027. The Sandoz settlement follows settlements with Glenmark, Lannett, Bausch, Apotex and Heritage, and Heritage’s parent company, Emcure, totaling $96.5 million.